Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Muscadine Grape Extract (MGE) in Advanced Malignancy

NCT02583269 is registered in ClinicalTrials.gov with Wake Forest University Health Sciences as lead sponsor.

NCT NCT02583269
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02583269 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Muscadine Grape Extract (MGE) in Advanced Malignancy
Lead sponsor
Wake Forest University Health Sciences
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2016
Completion date
April 24, 2023
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant neoplasm, metastatic malignant neoplasm, unresectable malignant neoplasm